- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07939750
Sotagliflozin Versus Empagliflozin Added to Metformin for Glycemic Control in Type 2 Diabetes
Comparison of the Effect of Metformin-Sotagliflozin Versus Metformin-Empagliflozin Combination Therapy on Glycemic Control Measured by HbA1c in Patients With Type 2 Diabetes Mellitus
The goal of this randomized controlled trial is to compare two medicines added to metformin for blood sugar control in adults with type 2 diabetes whose HbA1c remains between 7.0% and 10.0% despite a stable dose of metformin. The main question it aims to answer is: Does adding sotagliflozin (a dual SGLT1/SGLT2 inhibitor) lower HbA1c more than adding empagliflozin (a selective SGLT2 inhibitor) after 24 weeks? Participants will continue their usual metformin dose and will be randomly assigned to take either sotagliflozin 200 mg or empagliflozin 10 mg once daily for 24 weeks. They will be reviewed at 4, 12 and 24 weeks for adherence, side effects and adverse events, and HbA1c will be measured at baseline and at 24 weeks.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
Pakistan has one of the highest adult diabetes prevalences in the world, and many patients fail to reach HbA1c targets on metformin monotherapy and require a second agent. SGLT2 inhibitors such as empagliflozin are established second-line agents. Sotagliflozin additionally inhibits intestinal SGLT1, blunting post-prandial glucose absorption and enhancing incretin release, which may provide additional glucose lowering. No head-to-head randomized comparison of these two combinations has been performed in Pakistan.
This is a single-centre, open-label, parallel-group randomized controlled trial with blinded outcome assessment, conducted at the Department of Medicine and Diabetic Clinic/Medicine OPD, Allied Hospital-I, Faisalabad Medical University. 140 patients (70 per group) will be enrolled by consecutive sampling and randomized 1:1. Sample size was calculated for 95% confidence, 80% power, SD of HbA1c change 1%, and a minimal clinically important difference of 0.5%, inflated by 10% for loss to follow-up. HbA1c will be measured by a standardized laboratory method at baseline and 24 weeks, with laboratory staff blinded to group allocation. Data will be analysed in SPSS; mean change in HbA1c will be compared using the independent-samples t-test (p ≤ 0.05 significant), with stratification for age, gender, BMI, duration of diabetes and baseline HbA1c.
Studietype
Registrering (Antatt)
Fase
- Fase 4
Kontakter og plasseringer
Studiekontakt
- Navn: Sheraz Ali
- Telefonnummer: +923330360744
- E-post: sheraz.mirza10@gmail.com
Studiesteder
-
-
Punjab Province
-
Faisalabad, Punjab Province, Pakistan, 38000
- Allied Hospital, Faisalabad Medical University
-
Ta kontakt med:
- Sheraz Ali
- Telefonnummer: 03330360744
- E-post: sheraz.mirza10@gmail.com
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Age 30 to 65 years, male or female
- Diagnosed type 2 diabetes mellitus (ADA criteria)
- Inadequately controlled on metformin: stable dose ≥1500 mg/day (or maximum tolerated dose) for at least 8 weeks, with HbA1c ≥7.0% and ≤10.0% at screening
- Willing to provide written informed consent and attend scheduled follow-up
Exclusion Criteria:
- Type 1 diabetes mellitus or secondary diabetes
- Use of any SGLT inhibitor, GLP-1 receptor agonist, DPP-4 inhibitor or sulfonylurea within the previous 8 weeks
- eGFR <45 mL/min/1.73 m², or significant hepatic impairment
- Pregnancy, lactation, or women of childbearing potential not using contraception
- Haemoglobinopathies
- Known hypersensitivity to any study drug, or any condition making the patient unsuitable for the trial
- Recurrent genital/urinary tract infections or history of Fournier's gangrene
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Enkelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Metformin + Sotagliflozin (Group A)
Existing stable dose of metformin plus sotagliflozin 200 mg orally once daily for 24 weeks. |
200 mg tablet orally once daily for 24 weeks continued at the participant's existing stable dose (≥1500 mg/day or maximum tolerated) |
|
Aktiv komparator: Metformin + Empagliflozin (Group B)
Existing stable dose of metformin plus empagliflozin 10 mg orally once daily for 24 weeks. |
continued at the participant's existing stable dose (≥1500 mg/day or maximum tolerated) 10 mg tablet orally once daily for 24 weeks |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in HbA1c From Baseline to Week 24
Tidsramme: Baseline and 24 weeks
|
Glycated haemoglobin (%) measured by a standardized laboratory method. Change calculated as baseline HbA1c minus week-24 HbA1c for each participant; a between-group difference ≥0.5% is considered clinically meaningful. |
Baseline and 24 weeks
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of Participants With Adverse Events
Tidsramme: Up to 24 weeks (assessed at weeks 4, 12 and 24)
|
Adverse events including genital/urinary tract infections, hypoglycaemia and gastrointestinal symptoms, recorded at follow-up visits. |
Up to 24 weeks (assessed at weeks 4, 12 and 24)
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Sheraz Ali, Faisalabad Medical University
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Sykdommer i det endokrine systemet
- Metabolske sykdommer
- Glukosemetabolismeforstyrrelser
- Sukkersyke
- Ernæringsmessige og metabolske sykdommer
- Diabetes mellitus, type 2
- Organiske kjemikalier
- Biguanider
- Guanidiner
- Amidines
- Metformin
- (2S,3R,4R,5S,6R)-2-(4-klor-3-(4-etoksybenzyl)fenyl)-6-(metyltio)tetrahydro-2H-pyran-3,4,5-triol
- Empagliflozin
Andre studie-ID-numre
- 48.ERC/FMU/2025-26/434
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
Individual participant data will not be shared; aggregate results will be published in a peer-reviewed journal.
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .